CA2952818A1 - Compositions pour le traitement de l'epistaxis - Google Patents

Compositions pour le traitement de l'epistaxis Download PDF

Info

Publication number
CA2952818A1
CA2952818A1 CA2952818A CA2952818A CA2952818A1 CA 2952818 A1 CA2952818 A1 CA 2952818A1 CA 2952818 A CA2952818 A CA 2952818A CA 2952818 A CA2952818 A CA 2952818A CA 2952818 A1 CA2952818 A1 CA 2952818A1
Authority
CA
Canada
Prior art keywords
composition
group
phenylephrine
combinations
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2952818A
Other languages
English (en)
Inventor
Eran Eilat
Evgenia LOZINSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topitech Pharma Israel Ltd
Original Assignee
Topitech Pharma Israel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topitech Pharma Israel Ltd filed Critical Topitech Pharma Israel Ltd
Publication of CA2952818A1 publication Critical patent/CA2952818A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2952818A 2015-05-01 2015-05-01 Compositions pour le traitement de l'epistaxis Abandoned CA2952818A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/001451 WO2016178053A1 (fr) 2015-05-01 2015-05-01 Compositions pour le traitement de l'epistaxis

Publications (1)

Publication Number Publication Date
CA2952818A1 true CA2952818A1 (fr) 2016-11-10

Family

ID=57218149

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2952818A Abandoned CA2952818A1 (fr) 2015-05-01 2015-05-01 Compositions pour le traitement de l'epistaxis

Country Status (5)

Country Link
EP (1) EP3288636A4 (fr)
CN (1) CN107073293A (fr)
CA (1) CA2952818A1 (fr)
IL (1) IL249640A0 (fr)
WO (1) WO2016178053A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11724985B2 (en) 2020-05-19 2023-08-15 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058657A1 (fr) * 2017-04-04 2018-10-11 Anti-Plasmin Technologies, Llc Procedes destines a ameliorer un traitement medical non chirurgical
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212952A1 (fr) 2019-04-17 2020-10-22 Compass Pathfinder Limited Traitement de la dépression et de divers autres troubles au moyen de psilocybine
US11654057B2 (en) 2020-04-09 2023-05-23 Bio 54, Llc Devices for bleeding reduction and methods of making and using the same
US11642324B1 (en) * 2022-03-01 2023-05-09 Bio 54, Llc Topical tranexamic acid compositions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
AU2005262070B2 (en) * 2004-07-09 2011-01-27 Ferrosan Medical Devices A/S Haemostatic composition comprising hyaluronic acid
HUE046071T2 (hu) * 2009-10-30 2020-01-28 Intratus Inc Eljárások és készítmények gyógyszerek elnyújtott hatóanyagleadására
WO2014064703A1 (fr) * 2012-10-28 2014-05-01 Peritech Pharma Ltd. Compositions adhésives liquides pharmaceutiques pour le traitement de troubles anorectaux
KR20150136077A (ko) * 2013-03-10 2015-12-04 페리테크 파마 엘티디. 국소 조성물 및 국소 질환의 치료 방법

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11724985B2 (en) 2020-05-19 2023-08-15 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11746088B2 (en) 2020-05-19 2023-09-05 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11834410B2 (en) 2020-05-19 2023-12-05 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11958807B2 (en) 2020-05-19 2024-04-16 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use

Also Published As

Publication number Publication date
EP3288636A4 (fr) 2019-01-16
EP3288636A1 (fr) 2018-03-07
IL249640A0 (en) 2017-02-28
CN107073293A (zh) 2017-08-18
WO2016178053A1 (fr) 2016-11-10

Similar Documents

Publication Publication Date Title
US10085995B2 (en) Topical compositions and methods of treatment of anorectal disorders
CA2952818A1 (fr) Compositions pour le traitement de l'epistaxis
JP6267218B2 (ja) 揮発性、疎水性溶媒を用いた生物学的に活性な薬剤の送達
RU2754846C1 (ru) Обезболивающие композиции местного действия
JP6093007B2 (ja) 基質に有効成分を送達するためのシリコーン系賦形剤を含有する局所用製剤組成物
US7939570B2 (en) Controlled-release composition for topical application and a method of delivering an active agent to a substrate
JP2012532222A (ja) 膜形成シリコーン含有組成物
WO2014064703A1 (fr) Compositions adhésives liquides pharmaceutiques pour le traitement de troubles anorectaux
JP2008534483A (ja) 経皮局所用組成物およびその使用
ES2875381T3 (es) Formulación tópica
US20150366798A1 (en) Pharmaceutical adhesive compositions for treatment of epistaxis and methods of use thereof
JP2018177724A (ja) 外用薬
JP5241104B2 (ja) 外用組成物
WO2015185979A1 (fr) Compositions ano-rectales comprenant un anesthésique sous forme de base libre et un vasoconstricteur sous forme de sel
US20240115528A1 (en) Composition for external application
BR112020012195A2 (pt) composições e métodos para prevenir e tratar condições
JP3568881B2 (ja) 皮膚疾患治療用外用剤
GB2596286A (en) Topical formulations containing a primary active and ancillary actives
CN114585363A (zh) 新型儿科组合物

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190501